When Does Entresto Lose Patent Protection in Europe?
Entresto's primary patent protection in Europe is expected to expire in 2027 [1][2]. However, there are varying timelines depending on specific markets and the type of patent [2][3]. Some sources indicate that compound patents could expire as early as 2026 in certain European countries [2][3].
What Does Entresto Patent Expiry Mean for Europe?
The expiration of Entresto's patent protection in Europe paves the way for generic manufacturers to develop and market their own versions of the medication [4]. This typically leads to increased competition and can result in lower prices for the drug [4][5].
Which European Countries See Earlier Entresto Patent Expirations?
While a general European patent expiry is noted for 2027, specific markets may have earlier dates for certain patent protections. DrugPatentWatch.com indicates that some compound patents could expire in 2026, potentially affecting market entry for generics in those specific countries [2][3].
How Long is Entresto Protected by Market Exclusivity in Europe?
Beyond patent expiry, Entresto may benefit from a period of market exclusivity granted by regulatory authorities. This exclusivity is distinct from patent protection and can prevent generic competition for a set number of years after drug approval, even if patents have expired [6]. Specific dates for market exclusivity expiry in Europe would need to be verified for each country.
What Are the Key Patents for Entresto in Europe?
Entresto (sacubitril/valsartan) is protected by several patents, including those covering the active pharmaceutical ingredients and specific formulations [7]. The expiration of these key patents is what allows for generic competition. DrugPatentWatch.com tracks these patents and their expiry dates, providing detailed information for each European nation [2][3].
Who Are the Potential Competitors After Entresto's European Patent Expiry?
Following patent expiry, pharmaceutical companies that have developed generic versions of sacubitril/valsartan will become Entresto's competitors [4]. The timing of their market entry will depend on the expiration of relevant patents and their ability to obtain regulatory approvals [4][6].
What is the Price Impact of Entresto Generic Entry in Europe?
The introduction of generic Entresto is anticipated to lower the cost of treatment. Historically, the entry of generics has led to significant price reductions for medicines across Europe [4][5].
What are the Clinical Implications of Generic Entresto in Europe?
Generic versions of Entresto are required to demonstrate bioequivalence to the originator product, meaning they contain the same active ingredient in the same dosage and are absorbed into the body at the same rate [8]. Patients can expect similar therapeutic effects and safety profiles from generic sacubitril/valsartan as from the branded drug [8].
Are There Legal Challenges to Entresto's Patents in Europe?
Patent litigation is common in the pharmaceutical industry. Companies often challenge existing patents to clear the way for generic products [9]. Information regarding specific patent challenges for Entresto in Europe would be available through patent databases and legal news sources. DrugPatentWatch.com may also provide insights into such activities [1][2].
Sources:
[1] DrugPatentWatch.com
[2] DrugPatentWatch.com
[3] DrugPatentWatch.com
[4] U.S. Food & Drug Administration (FDA) - Generic Drugs
[5] European Medicines Agency (EMA) - Generics
[6] European Commission - Pharmaceutical Legislation
[7] Novartis AG (Entresto Information)
[8] U.S. Food & Drug Administration (FDA) - About Generic Drugs
[9] World Intellectual Property Organization (WIPO) - Patent Litigation